Fosfomycin: Prospective analysis of 100 treatment courses in a pediatric oncological center;Fosfomycin: Prospektive analyse von 100 behandlungskursen in einem pädiatrisch onkologischen zentrum

Chemotherapie Journal

Volumn 17, Issue 1, 2008, Pages 25-28

  Hepping, Nico ^a   Bode, Udo ^a   Fleischhack, Gudrun ^a   Wiszniewsky, Gertrud ^a   Molitor, Ernst ^b   Simon, Arne ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; LINEZOLID; PIPERACILLIN; TAZOBACTAM; TEICOPLANIN;

ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; HUMAN; INFECTION; METHODOLOGY; MONOTHERAPY; PEDIATRIC HOSPITAL; PROSPECTIVE STUDY; STAPHYLOCOCCUS INFECTION;

EID: 39649106356     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J Antimicrob Chemother 1999;43:211-7.
2. Corti N, Sennhauser FH, Stauffer UG, Nadal D. Fosfomycin for the initial treatment of acute haematogenous osteomyelitis. Arch Dis Child 2003;88:512-6.
3. Grif K, Dierich MP, Pfaller K, Miglioli PA, et al. In vitro activity of fosfomycin in combination with various antistaphylococcal substances. J Antimicrob Chemother 2001;48:209-17.
4. Hamilton-Miller JM. In vitro activity of fosfomycin against "problem" gram-positive cocci. Microbios 1992;71:95-103.
5. Joukhadar C, Klein N, Dittrich P, Zeitlinger M, et al. Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 2003;51:1247-52.
6. Pfausler B, Spiss H, Dittrich P, Zeitlinger M, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother 2004;53:848-52.
7. Shrestha NK, Chua JD, Tuohy MJ, Wilson DA, et al. Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin. Scand J Infect Dis 2003;35:12-4.
8. Simon A, Bode U, Fleischhack G, Kramer M. Surveillance of nosocomial infections in pediatric cancer patients. Am J Infect Control 2005;33:611.
9. Simon A, Fleischhack G, Hasan C, Bode U, et al. Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 2000;21:592-6.
10. Simon A, Ammann RA, Bode U, Fleischhack G, et al. Nosocomial infections in pediatric cancer patients: results of a prospective surveillance study from 7 university hospitals in Germany. 2007;Manuscript in preparation.
11. Andrews JM, Baquero F, Beltran JM, Canton E, et al. International collaborative study on standardization of bacterial sensitivity to fosfomycin. J Antimicrob Chemother 1983;12:357-61.
12. Simon A, Groger N, Wilkesmann A, Hasan C, et al. Restricted use of Glykopeptides in paediatric cancer patients with fever and neutropenia. Int J Antimicrob Agents 2006;28:417-22.